Since consumption of calorie-dense palatable foods is highly pertinent to the onset and maintenance of obesity and diabetes, the potential modulation of taste sensitivity and food preference upon treatment with GLP-1-based therapies is of important clinical relevance. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.